CSF3 and acute myeloid leukemia: In phase I/II study of AMD3100 in combination with fludarabine, idarubicin, cytarabine and G‐CSF (FLAG‐Ida) for the treatment of patients with early‐relapsed or refractory AML, the CR/CRi rate was 50% among primary refractory and 47% among early‐relapsed patients, and three patients died during induction.66